Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 10/20 | 1.00 |
| ▸ | RAB9A | P51151 | 10/20 | 1.00 |
| ▸ | ATAD2 | Q6PL18 | 2/20 | 1.00 |
| ▸ | PKM | P14618 | 2/20 | 0.82 |
| ▸ | TP53 | P04637 | 1/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.77 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.61 |
| ▸ | RELA | Q04206 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883712 | 0.91 | PKM (1.00) | NPC1RAB9AATAD2PKMTP53 | |
| SCHEMBL46426 | 0.88 | NPC1 (1.00) | NPC1RAB9AATAD2TP53SMN1; SMN2 | |
| SCHEMBL13134534 | 0.87 | NPC1 (0.76) | NPC1RAB9AATAD2PKMTP53 | |
| SCHEMBL9612006 | 0.86 | PKM (0.90) | NPC1RAB9AATAD2PKMTP53 | |
| SCHEMBL11965041 | 0.86 | PKM (0.90) | NPC1RAB9AATAD2PKMTP53 | |
| SCHEMBL4343181 | 0.85 | NPC1 (0.94) | NPC1RAB9AATAD2TP53SMN1; SMN2 | |
| SCHEMBL38657585 | 0.84 | NPC1 (0.72) | NPC1RAB9AATAD2PKMTP53 | |
| SCHEMBL46424 | 0.83 | NPC1 (0.90) | NPC1RAB9AATAD2TP53SMN1; SMN2 | |
| SCHEMBL22858502 | 0.83 | NPC1 (0.90) | NPC1RAB9AATAD2TP53SMN1; SMN2 | |
| SCHEMBL522555 | 0.83 | NPC1 (0.90) | NPC1RAB9AATAD2TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220104493-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2022-04-07 | — | — | US | disclosed |
| EP-3920701-A1 | HERBICIDAL COMPOUNDS | Syngenta Crop Protection AG (CH) | 2021-12-15 | — | — | EP | disclosed |
| CN-113412055-A | Herbicidal compounds | 先正达农作物保护股份公司 | 2021-09-17 | — | — | CN | disclosed |
| WO-2020161163-A1 | HERBICIDAL COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2020-08-13 | — | — | WO | disclosed |
| WO-2015081280-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| WO-2015081284-A1 | BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME | COFERON, INC. (US) | 2015-06-04 | — | — | WO | disclosed |
| US-8153645-B2 | Use of analgesics to treat chronic pain using sodium channel modulators | ALLERGAN, INC. (US) | 2012-04-10 | — | — | US | disclosed |
| US-8124612-B2 | Treating neurological disorders using selective antagonists of persistent sodium current | ALLERGAN, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-7767718-B2 | Treating pain using selective antagonists of persistent sodium current | ALLERGAN, INC. (US) | 2010-08-03 | — | — | US | disclosed |
| US-7763651-B2 | Treating pain using selective antagonists of persistent sodium current | ALLERGAN, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20060106103-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | ALLERGAN, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050238917-A1 | Charge transporting polymer and production process thereof, and polymer composition for organic electroluminescence device and organic electroluminescence device | JSR CORPORATION (JP) | 2005-10-27 | — | — | US | disclosed |
| EP-1589595-A2 | Charge transporting polymer and production process thereof, and polymer composition for organic electroluminescence device and organic electroluminescence device | JSR Corporation (JP) | 2005-10-26 | — | — | EP | disclosed |
| EP-1582550-A1 | Polymer for organic el element, composition for organic el element, and organic el element | JSR Corporation (JP) | 2005-10-05 | — | — | EP | disclosed |
| US-20050214574-A1 | Polymer for organic EL element, composition for organic EL element, and organic EL element | JSR CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| US-20050054695-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | ALLERGAN, INC. | 2005-03-10 | — | — | US | disclosed |
| WO-2005020982-A2 | USING SELECTIVE ANTAGONISTS OF PERSISTENT SODIUM CURRENT TO TREAT NEUROLOGICAL DISORDERS AND PAIN | ALLERGAN, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| US-20050049287-A1 | Treating pain using selective antagonists of persistent sodium current | ALLERGAN, INC. | 2005-03-03 | — | — | US | disclosed |
| EP-1469057-A2 | Polymer, polymer for forming organic electroluminescence device, polymer composition for organic electroluminescence device and organic electroluminescence device | JSR Corporation (JP) | 2004-10-20 | — | — | EP | disclosed |
| US-20040202892-A1 | Polymer, polymer for forming organic electroluminescence device, polymer composition for organic electroluminescence device and organic electroluminescence device | JSR CORPORATION (JP) | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220104493-A1 | HERBICIDAL COMPOUNDS | DDT, ACHE, GSTO1 | NPC1 3704/4885RAB9A 2178/4885ATAD2 3738/4885 |
| US-20050049287-A1 | Treating pain using selective antagonists of persistent sodium current | KCNN3, KCNN2, SCN1B | NPC1 1078/4885RAB9A 3434/4885ATAD2 3432/4885 |
| US-20050054695-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | SCN1A, KCNN2, KCNN1 | NPC1 498/4885RAB9A 2352/4885ATAD2 2799/4885 |
| US-20060106103-A1 | Treating neurological disorders using selective antagonists of persistent sodium current | SCN1A, KCNN2, KCNN1 | NPC1 498/4885RAB9A 2352/4885ATAD2 2799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.